Hemoglobin S Allosteric Modulators for Oxygen Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics are inadequate for treating disorders mediated by abnormal hemoglobin, such as sickle cell disease, which requires effective modulation of hemoglobin to improve oxygen affinity and reduce tissue and cellular oxygen deficiency.
Innovation Solution
Development of specific compounds and pharmaceutical compositions that act as allosteric modulators of hemoglobin, specifically targeting hemoglobin S to increase oxygen affinity and treat related disorders by administering a therapeutically effective amount of these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allosteric modulators of hemoglobin are administered, then oxygen affinity of hemoglobin S is increased, but the complexity of the therapeutic regimen increases
Solution Approach 1:
The patent modifies chemical parameters by developing specific compounds with optimized molecular structures (Formula I with defined ring systems and substituents) that selectively bind to hemoglobin S. This changes the biochemical parameter of oxygen affinity without requiring complex delivery systems or combination therapies, thus improving reliability while managing therapeutic complexity.
2Reliability
If compounds are developed to treat sickle cell disease, then oxygen deficiency is reduced, but the time required for drug development increases
Solution Approach 1:
The patent performs preliminary structural design by defining specific chemical frameworks (Formula I with rings A, B, C and defined substituents) that are predicted to interact with hemoglobin S. This preliminary molecular design approach allows for more efficient optimization and testing, reducing overall development time while ensuring the compounds achieve the desired oxygenation effects.
3Reliability
If allosteric modulators are used to treat hemoglobin disorders, then oxygen affinity is improved, but the manufacturing complexity of the compounds increases
Solution Approach 1:
The patent segments the molecular structure into distinct modular components (ring A, ring B, ring C, and various substituent positions) that can be independently optimized and synthesized. This segmentation allows for parallel synthesis routes and simplifies manufacturing by enabling the production of individual fragments that are then assembled, reducing overall manufacturing complexity while maintaining high oxygen affinity.
Data Source
AI summary
Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.